List view / Grid view
27 November 2013 | By Mettler Toledo
Mettler-Toledo announced an upcoming webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing" with special guest presenter Mr. Gregory Martin, President of Complectors Consulting LLC...
26 November 2013 | By kdm communications limited
Complementing the laboratory’s existing liquid displacement Freedom EVO platforms for DNA extraction, this new instrument will help to streamline the workflow and improve pipetting precision...
26 November 2013 | By Boehringer Ingelheim
The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...
25 November 2013 | By Cubist
“We are very pleased with these positive results, which represent a significant milestone for both ceftolozane/tazobactam and Cubist...”
25 November 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical…
25 November 2013 | By TEVA
Teva Pharmaceutical Industries Ltd. issued the following statement regarding an article published by The Marker...
25 November 2013 | By GlaxoSmithKline
The U.S. Food and Drug Administration has eased restrictions on patient access to Avandia (rosiglitazone)...
25 November 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the FDA has approved its pandemic Influenza A Virus Monovalent Vaccine...
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
22 November 2013 | By Johnson & Johnson
OLYSIO™ works by blocking the viral protease enzyme that enables the hepatitis C virus (HCV) to replicate in host cells...
22 November 2013 | By Biogen Idec
This designation will provide 10 years of regulatory exclusivity for TECFIDERA in the European Union...
22 November 2013 | By AstraZeneca
Xigduo™ combines dapagliflozin (tradename Forxiga®), a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride in a twice daily tablet...
22 November 2013 | By Amgen
First and only FDA-approved treatment option for patients with this type of thyroid cancer...
21 November 2013 | By GlaxoSmithKline
“We welcome the CHMP’s positive opinion on dolutegravir – it puts us a step closer to offering this new treatment option to people across Europe who are living with HIV...”
20 November 2013 | By Zealand Pharma
Zealand Pharma A/S announces that the first patient has been treated in a Phase II Clinical Proof-of-Concept study of danegaptide...
